2013
TCT-20 Two-Year Clinical Follow-Up of the FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions: The TARGET I Trial
Xu B, Gao R, Lansky A, Yang Y, Changsheng M, Han Y, Chen S, Li H, Zhang R, Fu G, Yuan Z, Huo Y, Li W, Zhao Y, Leon M. TCT-20 Two-Year Clinical Follow-Up of the FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions: The TARGET I Trial. Journal Of The American College Of Cardiology 2013, 62: b7-b8. DOI: 10.1016/j.jacc.2013.08.748.Peer-Reviewed Original ResearchDe novo native coronary artery lesionsBiodegradable Polymer Sirolimus-Eluting StentNovo native coronary artery lesionsNative coronary artery lesionsCoronary artery lesionsSirolimus-Eluting StentsTreatment of patientsTwo-Year ClinicalAbluminal grooveArtery lesionsI trialPatientsClinicalLesionsStentsTrialsEvaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years
Forrest JK, Lansky AJ, Meller SM, Hou L, Sood P, Applegate RJ, Wang JC, Skelding KA, Shah A, Kereiakes DJ, Sudhir K, Cristea E, Yaqub M, Stone GW. Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years. The American Journal Of Cardiology 2013, 111: 1580-1586. PMID: 23499270, DOI: 10.1016/j.amjcard.2013.01.330.Peer-Reviewed Original ResearchConceptsSPIRIT IV trialMajor adverse cardiac eventsAdverse cardiac eventsClinical outcomesXIENCE VTarget lesionsCardiac eventsNovo native coronary artery lesionsIschemia-driven target vessel revascularizationTwo-year clinical outcomesNative coronary artery lesionsSPIRIT IIISide branchesXIENCE V EverolimusTarget lesion failureTarget vessel revascularizationCoronary artery lesionsPercutaneous coronary interventionSuperior clinical outcomesTreatment of patientsCoronary stent systemDrug-eluting stentsDiverse patient populationsEverolimus-ElutingSPIRIT IV
2009
Clinical and angiographic outcomes with an everolimus‐eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry
Gordon PC, Applegate RJ, Hermiller JB, Weinsier SB, Doostzadeh J, Cao S, Sudhir K, Lansky AJ, Stone GW. Clinical and angiographic outcomes with an everolimus‐eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry. Catheterization And Cardiovascular Interventions 2009, 75: 179-186. PMID: 19877267, DOI: 10.1002/ccd.22259.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelPredictive Value of TestsProspective StudiesRegistriesRisk AssessmentSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsMajor adverse cardiac eventsTarget vessel failureSegment late lossSPIRIT III trialLarge coronary arteriesPaclitaxel-eluting stentsLate lossCoronary arteryIII trialsXIENCE VDe novo native coronary artery lesionsNovo native coronary artery lesionsNative coronary artery lesionsPE armSPIRIT IIIAdverse cardiac eventsCoronary artery lesionsAdverse clinical eventsAngiographic late lossEES patientsNoninferior ratesPrimary endpointAngiographic outcomesArtery lesionsCardiac eventsSPIRIT IV trial design: A large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease
Nikolsky E, Lansky AJ, Sudhir K, Doostzadeh J, Cutlip DE, Piana R, Su X, White R, Simonton CA, Stone GW. SPIRIT IV trial design: A large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. American Heart Journal 2009, 158: 520-526.e2. PMID: 19781409, DOI: 10.1016/j.ahj.2009.07.025.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsTarget lesion revascularizationCoronary artery diseaseSPIRIT IVLesion revascularizationArtery diseaseDiabetes mellitusIschemia-driven target lesion revascularizationNovo native coronary artery lesionsMajor adverse cardiac eventsNative coronary artery diseaseNative coronary artery lesionsTarget vessel myocardial infarctionEnd pointUS clinical sitesAdverse cardiac eventsPrimary end pointTarget lesion failureTarget vessel failureVessel myocardial infarctionCoronary artery lesionsReference vessel diameterClinical end pointsMulticenter clinical trialAngiographic late loss